Department of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Am Acad Dermatol. 2018 Sep;79(3):479-486. doi: 10.1016/j.jaad.2017.12.053. Epub 2017 Dec 27.
Q-switched alexandrite lasers (QSALs) have been used for the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs). Currently, picosecond alexandrite laser (PSAL) pulses have become available for pigmentary disorders. However, no studies have compared PSAL and QSAL in the treatment of ABNOM.
We sought to compare the efficacy and safety of PSAL and QSAL in the treatment of ABNOM.
Each patient (n = 30) received 3 treatments at 6-month intervals. Matching areas were delimitated on the face of each patient (left/right comparison); 1 side was treated with PSAL and the other side was treated with QSAL. The safety and efficacy of the 2 lasers were determined by visual assessment and self-report from patients 6 months after the final treatment.
The PSAL-treated area achieved significantly better clearance (3.73 vs 2.4) with less severe pain (4.47 vs 5.16). The incidence rate of postinflammatory hyperpigmentation was 27.77% and 54.44% for the PSAL and QSAL treatments, respectively, and the duration of postinflammatory hyperpigmentation was 1.32 and 1.74 months, respectively (P < .001).
The limitations of our study include the small sample size and the lack of objective evaluation.
Compared with QSAL, PSAL therapy afforded significantly better clinical outcomes and fewer side effects in the treatment of ABNOM.
调 Q 开关紫翠宝石激光（QSAL）已被用于治疗获得性双侧太田痣样斑（ABNOM）。目前，皮秒紫翠宝石激光（PSAL）脉冲已可用于治疗色素性疾病。然而，目前尚无研究比较 PSAL 和 QSAL 在 ABNOM 治疗中的疗效。
我们旨在比较 PSAL 和 QSAL 在 ABNOM 治疗中的疗效和安全性。
每位患者（n=30）每 6 个月接受 3 次治疗。在每位患者的面部划定匹配区域（左右比较）；一侧用 PSAL 治疗，另一侧用 QSAL 治疗。治疗结束后 6 个月，通过患者的视觉评估和自我报告来确定两种激光的安全性和疗效。
PSAL 治疗区域的清除率明显更高（3.73 比 2.4），疼痛程度较轻（4.47 比 5.16）。PSAL 和 QSAL 治疗的炎症后色素沉着发生率分别为 27.77%和 54.44%，炎症后色素沉着持续时间分别为 1.32 个月和 1.74 个月（P<0.001）。
本研究的局限性包括样本量小和缺乏客观评估。
与 QSAL 相比，PSAL 治疗在治疗 ABNOM 时提供了更好的临床效果和更少的副作用。
